| 0.8 -0.105 (-11.57%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.25 |
1-year : | 1.46 |
| Resists | First : | 1.07 |
Second : | 1.25 |
| Pivot price | 0.98 |
|||
| Supports | First : | 0.79 |
Second : | 0.65 |
| MAs | MA(5) : | 0.88 |
MA(20) : | 1.01 |
| MA(100) : | 1.05 |
MA(250) : | 1.29 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.5  |
D(3) : | 9.3 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 1.95 | Low : | 0.75 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TLSA ] has closed below the lower bollinger band by 4.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TLSA ] is to continue within current trading range. Bollinger Bands are 9.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.92 | 0.92 - 0.93 |
| Low: | 0.78 - 0.78 | 0.78 - 0.79 |
| Close: | 0.79 - 0.8 | 0.8 - 0.81 |
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
Fri, 30 Oct 2026
Tiziana Life Sciences Ltd (TLSA) Seasonal returns chart - Yahoo Finance UK
Wed, 21 Oct 2026
Tiziana Life Sciences to discuss foralumab programs at Toronto MS meeting - Proactive financial news
Fri, 16 Oct 2026
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab | NASDAQ:TLSA - Proactive financial news
Fri, 16 Oct 2026
Tiziana Life Sciences Announces Last Patient Dosed in Phase 2 Trial of Intranasal Foralumab for Early Alzheimer’s Disease - Quiver Quantitative
Fri, 16 Oct 2026
The last patient starts dosing in Tiziana (TLSA)’s Phase 2 Alzheimer’s trial. - Stock Titan
Wed, 30 Sep 2026
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 127 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 47.3 (%) |
| Held by Institutions | 2 (%) |
| Shares Short | 2,640 (K) |
| Shares Short P.Month | 1,700 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -103.2 % |
| Return on Equity (ttm) | -780.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -3.81 |
| PEG Ratio | 0 |
| Price to Book value | -40 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|